Chennai Meena

Why is Chennai Meenakshi Multispeciality Hospital Ltd falling/rising?

As of 01-Sep, the stock price of Chennai Meenakshi Multispeciality Hospital Ltd is rising to 38.39, driven by strong investor participation and outperforming its sector. However, it remains below its moving averages, suggesting potential long-term downward trends despite short-term gains.

As of 01-Sep, the stock price of Chennai Meenakshi Multispeciality Hospital Ltd is rising, currently at 38.39, with a change of 0.89 (2.37%) upwards. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.59% today, indicating a relatively strong performance compared to its peers. Additionally, there has been a notable rise in investor participation, with the delivery volume on 31 August increasing by 129.51% compared to the 5-day average, suggesting heightened interest from investors.<BR><BR>However, it is important to note that despite the current rise, the stock is trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates that while there is a short-term upward movement, the longer-term trend may still be downward. Overall, the combination of today's outperformance and increased investor activity contributes to the stock's rising price.

Which are the latest news on Chennai Meena?

Who are in the management team of Chennai Meena?

The management team of Chennai Meena consists of R Gomathi (Managing Director), K. Meyyanathan, N. Rajkumar, and Jayanthi Radhakrishnan (all Independent Directors).

The management team of Chennai Meena includes the following members:<BR><BR>1. R Gomathi - Managing Director<BR>2. K. Meyyanathan - Independent Director<BR>3. N. Rajkumar - Independent Director<BR>4. Jayanthi Radhakrishnan - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Chennai Meena do?

Chennai Meenakshi Multispeciality Hospital Ltd, established in 1990 and formerly known as Devaki Hospital, operates in the healthcare sector as a micro-cap company with recent net sales of 9 Cr and a market cap of INR 29 Cr. The company is currently loss-making, with a P/E ratio of N/A and a debt-equity ratio of -1.76.

Overview:<BR>Chennai Meenakshi Multispeciality Hospital Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1990 and was formerly known as Devaki Hospital Limited until it changed its name in October 2007. The most recent quarterly results report net sales for June 2026.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 9 Cr (Quarterly Results - Jun 2026)<BR>- Most recent Net Profit: N/A<BR>- Market-cap value: INR 29 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.76<BR>- Return on Equity: 13.36%<BR>- Price to Book: -9.30<BR><BR>Contact Details:<BR>- Address: New No 70 Old No 149, Luz Church Road Mylapore Chennai Tamil Nadu : 600004<BR>- Tel: 91-044-42938938<BR>- Email: cmmhospitals@gmail.com<BR>- Website: https://cmmh.in

Who are the peers of the Chennai Meena?

Chennai Meena's peers include GKB Ophthalmics, Deccan Healthcar, Bandaram Pharma, and others. Galaxy Medicare has the highest 1-year return at 0.00%, while Bandaram Pharma has the lowest at -41.87%, with Chennai Meena's return at -1.32%.

Peers: The peers of Chennai Meena are GKB Ophthalmics, Deccan Healthcar, Bandaram Pharma, Tejnaksh Health., Adeshwar Meditex, Samsrita Labs, Transgene Biotek, Vanta Bioscience, and Galaxy Medicare.<BR><BR>Quality Snapshot: Below Average management risk is observed at GKB Ophthalmics, Deccan Healthcar, Bandaram Pharma, Adeshwar Meditex, Vanta Bioscience, and the rest. Below Average growth is noted at Adeshwar Meditex, Tejnaksh Health., Vanta Bioscience, and the rest, while Excellent growth is found at Bandaram Pharma. Good capital structure is seen at GKB Ophthalmics, Deccan Healthcar, and the rest, while Average capital structure is present at Adeshwar Meditex, and Below Average at Bandaram Pharma, Vanta Bioscience, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Galaxy Medicare at 0.00%, while Bandaram Pharma has the lowest at -41.87%. Chennai Meena's 1-year return is -1.32%, which is better than Bandaram Pharma's but worse than Galaxy Medicare's. Additionally, peers with negative six-month returns include Deccan Healthcar, Bandaram Pharma, Samsrita Labs, and Vanta Bioscience.

How big is Chennai Meena?

As of 31st August, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 29.00 Cr and reported net sales of 36.98 Cr with a net loss of 0.41 Cr over the latest four quarters.

As of 31st August, Chennai Meenakshi Multispeciality Hospital Ltd has a market capitalization of 29.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 36.98 Cr. However, it experienced a net loss of 0.41 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's funds stood at a loss of 1.89 Cr, while total assets were valued at 22.51 Cr.

Should I buy, sell or hold Chennai Meenakshi Multispeciality Hospital Ltd?

When is the next results date for Chennai Meenakshi Multispeciality Hospital Ltd?

The next results date for Chennai Meenakshi Multispeciality Hospital Ltd is August 11, 2026.

The next results date for Chennai Meenakshi Multispeciality Hospital Ltd is scheduled for August 11, 2026.

Are Chennai Meenakshi Multispeciality Hospital Ltd latest results good or bad?

Chennai Meenakshi Multispeciality Hospital Ltd's latest results are concerning, showing a net loss of ₹0.02 crore in Q4 FY26 despite a 6.98% revenue increase, marking the second consecutive quarterly loss and highlighting ongoing operational challenges and a negative net worth.

Chennai Meenakshi Multispeciality Hospital Ltd's latest results indicate a challenging financial situation. In Q4 FY26, the company reported a net loss of ₹0.02 crore, a significant decline from a profit of ₹0.31 crore in the same quarter last year. While revenue increased by 6.98% year-on-year to ₹9.81 crore, this growth did not translate into profitability, marking the second consecutive quarterly loss for the company.<BR><BR>The operating margin also contracted to 2.55%, down 127 basis points from the previous year, highlighting ongoing operational challenges. Additionally, the company has a negative net worth, with a book value per share of negative ₹2.53, raising serious concerns about its financial stability and ability to invest in necessary improvements.<BR><BR>Overall, the results reflect a company struggling with fundamental operational issues, and the volatility in profitability raises questions about the sustainability of its business model.

How has been the historical performance of Chennai Meena?

Chennai Meena's historical performance shows declining net sales and profits, with revenue dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, and a shift from profit to loss in operating profit and net profit. Despite these challenges, total liabilities and cash flow from operations remained stable.

Answer:<BR>The historical performance of Chennai Meena shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Chennai Meena's net sales decreased from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25, reflecting a decline in revenue. The total operating income followed a similar trend, dropping from 38.74 Cr in Mar'23 to 34.82 Cr in Mar'25. The company experienced an operating profit (PBDIT) decline, moving from 3.35 Cr in Mar'23 to a loss of 0.21 Cr in Mar'25. Consequently, the profit before tax also fell from 1.28 Cr in Mar'23 to a loss of 1.43 Cr in Mar'25, leading to a profit after tax decline from 0.89 Cr to a loss of 1.37 Cr in the same period. The company's total liabilities remained relatively stable, with a slight decrease from 22.81 Cr in Mar'24 to 22.51 Cr in Mar'25. Cash flow from operating activities remained consistent at 2.00 Cr from Mar'22 to Mar'25, while the closing cash and cash equivalents were stable at 2.00 Cr in Mar'25. Overall, Chennai Meena's financial performance indicates challenges in profitability despite stable cash flow and liabilities.

Who are the top shareholders of the Chennai Meena?

The top shareholders of Chennai Meena are Jayanthi Radhakrishnan with 25.59%, followed by public shareholder Vijayan Abinaya at 10.06%. Individual investors own 60.51%, with no pledged promoter holdings or foreign institutional investors.

The top shareholders of Chennai Meena include Jayanthi Radhakrishnan, who holds the highest stake at 25.59%. The highest public shareholder is Vijayan Abinaya, with a holding of 10.06%. Additionally, individual investors collectively own 60.51% of the company. There are no pledged promoter holdings or foreign institutional investors involved, and mutual funds hold a small percentage through one scheme at 0.14%.

Is Chennai Meena overvalued or undervalued?

As of May 31, 2024, Chennai Meena's valuation has shifted from attractive to risky due to negative financial metrics, including a PE ratio of -17.17 and an EV to EBITDA of -30.42, indicating it is overvalued and underperforming compared to peers like Max Healthcare and Apollo Hospitals, as well as the Sensex.

As of 31 May 2024, the valuation grade for Chennai Meena has moved from attractive to risky, indicating a significant deterioration in its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of -17.17, an EV to EBITDA of -30.42, and a ROCE of -11.43%. These negative ratios suggest that the company is struggling to generate profits and manage its capital effectively.<BR><BR>In comparison to its peers, Chennai Meena's valuation stands out unfavorably. For instance, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals shows a PE of 69.03, both indicating a much stronger market position. The stark contrast in valuation ratios highlights that Chennai Meena is not only underperforming but also facing significant challenges relative to its competitors. Additionally, the company's stock has underperformed the Sensex over the past year, with a return of -8.52% compared to the Sensex's 7.58%, reinforcing the notion that it is currently overvalued.

What is the technical trend for Chennai Meena?

As of May 12, 2025, Chennai Meena's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 12 May 2025, the technical trend for Chennai Meena has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are bearish. The KST reflects a mildly bullish weekly trend but is mildly bearish monthly. The Dow Theory shows a mildly bullish weekly trend with no trend on the monthly. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the MACD and KST on the weekly chart.

Has Chennai Meena declared dividend?

No Dividend History Available